STEMRIM |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 470 JPY | 0.00% |
|
+4.44% | -18.69% |
| May. 09 | StemRIM to Seek Shareholders' Approval on Capital Stock Reduction | MT |
| Mar. 13 | StemRIM Announces Initiation of Phase 2 Clinical Trial for Redasemtide in Ischemic Cardiomyopathy | CI |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The company's earnings growth outlook lacks momentum and is a weakness.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -18.69% | 187M | - | ||
| -0.28% | 90.59B | A- | ||
| -0.92% | 38.99B | A- | ||
| -9.57% | 34.09B | B- | ||
| -17.98% | 15.02B | C | ||
| -6.74% | 13.17B | B- | ||
| -9.76% | 11.88B | D+ | ||
| -47.31% | 10.65B | B | ||
| +6.97% | 9.25B | B+ | ||
| +137.06% | 9.02B | D |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
-
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
-
Potential Price Target
-
4m Target Price Revision
-
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 4599 Stock
- Ratings StemRIM
